Skip to main content
Log in

Eszopiclone

A Review of Its Use in the Treatment of Insomnia

  • Adis Drug Evaluation
  • Published:
Drugs Aims and scope Submit manuscript

Summary

Abstract

Eszopiclone (Lunesta®), the S-enantiomer of racemic zopiclone, is a nonbenzodiazepine hypnotic agent that is approved in the US as an oral, once-nightly therapy for insomnia in adults; eszopiclone is also currently under review by the European Medicines Agency.

Eszopiclone is rapidly absorbed after oral administration without any next-day clinical residual effects being detected. Large, well designed trials of up to 6 months’ duration have shown that eszopiclone significantly improves both sleep onset and sleep maintenance compared with placebo in adult and elderly patients with primary insomnia. Eszopiclone for 4–8 weeks also significantly improved sleep parameters compared with placebo in patients with insomnia coexisting with other conditions that also disturb sleep (co-morbid insomnia), and improved certain measures of the co-morbid conditions to a greater extent than the standard therapies alone. Short-term eszopiclone produced improvements in daytime functioning in patients with co-morbid insomnia. Six months’ therapy in adults with primary insomnia improved daytime functioning and health-related quality of life. Eszopiclone was generally well tolerated. There was no evidence of tolerance during 12 months’ treatment with this agent. On discontinuation of eszopiclone, there was no rebound insomnia or serious withdrawal effects. Well designed, comparative trials with other nonbenzodiazepine hypnotics are needed to determine its relative efficacy and tolerability. A cost-utility analysis suggested that eszopiclone is cost effective for the treatment of primary insomnia in the US. Therefore, eszopiclone is a useful therapeutic option in the management of adult and elderly patients with primary or co-morbid insomnia. Unlike most other hypnotics, eszopiclone is not limited to short-term use.

Pharmacological Properties

Eszopiclone, a nonbenzodiazepine cyclopyrrolone, is the S-enantiomer of racemic zopiclone and has a greater affinity than the R-enantiomer for the GABAA/ benzodiazepine receptor complex; the sedative properties of racemic zopiclone are primarily linked to the S-rather than the R-enantiomer.

Eszopiclone 2 and 3 mg significantly improved polysomnography-assessed sleep parameters (sleep latency, wake time after sleep onset and sleep efficiency) compared with placebo in a model of transient insomnia in healthy, adult volunteers. Next-day clinical residual effects of eszopiclone were absent, as determined by standardized tests in healthy volunteers and patients with primary insomnia. Anxiolytic and muscle relaxant effects of eszopiclone have been demonstrated in animal studies.

Eszopiclone is rapidly absorbed after oral administration in healthy volunteers, with maximum plasma concentrations attained in ≈1 hour. Steady-state plasma concentrations were achieved 24–48 hours after initiation of once-daily administration, with no evidence of drug accumulation; pharmacokinetic parameters did not vary appreciably between single-dose and steady-state administration. The binding of eszopiclone to plasma proteins is 52–59%. The drug is metabolized via the cytochrome P450 (CYP) isoenzymes 3A4 and 2E1; metabolites are less active than the parent molecule at GABAa receptors. The mean elimination half-life of eszopiclone 3 mg was 5.8 hours (single dose) or 7 hours (steady state). No in vivo stereoconversion of eszopiclone to R-zopiclone was observed in an animal study. Total drug exposure is greater in elderly than in nonelderly adults, and in patients with severe hepatic impairment than in healthy volunteers; the maximum recommended dosage is less in these patients (2 mg/night) than in nonelderly adults (3 mg/night). No dosage adjustment is required in the US in patients with renal impairment. Coadministration of eszopiclone with inhibitors or inducers of CYP3A4 is likely to affect eszopiclone pharmacokinetics.

Therapeutic Efficacy

In well designed, placebo-controlled trials of ≤6 months’ duration, eszopiclone 2 (elderly patients) or 3 (adult patients) mg/night was effective in improving parameters relating to sleep onset and sleep maintenance in nonelderly and elderly patients with primary insomnia, and nonelderly patients with co-morbid insomnia. The co-morbid conditions were major depressive disorder, generalized anxiety disorder, menopausal transition and rheumatoid arthritis. Ratings for sleep quality, depth of sleep and daytime function also improved with eszopiclone therapy relative to placebo in both primary and co-morbid insomnia. No development of tolerance to eszopiclone 3 mg/night was observed in nonelderly adult patients with primary insomnia over a long-term (12-month) treatment period.

In patients with co-morbid insomnia, on stable standard therapies for their condition where appropriate, eszopiclone produced greater improvements than placebo in certain measures of the co-morbid conditions, such as the Hamilton Depression Rating Scale scores, Hamilton Anxiety Rating Scale scores, arthritis pain and ability to function scores, awakenings due to hot flushes and Greene Climacteric Scale scores.

Tolerability

Eszopiclone was generally well tolerated in clinical trials in adult patients with primary insomnia. The most frequent adverse event was unpleasant taste, which appeared to follow a dose-response relationship. Other common adverse events included headache, somnolence, dizziness and infection. There were few serious adverse events; in a 6-month trial, the proportion of eszopiclone recipients experiencing potentially treatment-related serious events was 0.3%. The rate of discontinuation due to adverse events did not differ between the eszopiclone and placebo groups in trials of ≤6 weeks’ duration or in one 6-month trial, but was significantly higher in the eszopiclone than the placebo group in another 6-month trial. The reasons for discontinuation in the latter trial included somnolence, depression and unpleasant taste. The adverse event profile of eszopiclone in patients with co-morbid insomnia was generally similar to that observed in patients with primary insomnia. Discontinuation of eszopiclone therapy did not result in rebound insomnia and no serious withdrawal syndrome was detected.

Pharmacoeconomic Considerations

A cost-utility analysis performed in the US suggested that 6 months’ treatment with eszopiclone 3 mg/night in adult patients with primary insomnia was cost effective compared with no treatment, especially from the societal perspective, which included productivity gains. The incremental cost-effectiveness ratio for eszopiclone versus no treatment was $US9930 per quality-adjusted life-year (QALY) gained for total costs and $US36 894 per QALY gained for direct costs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Table I
Table II
Table III
Table IV

Similar content being viewed by others

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. National Institutes of Health. National Institutes of Health state of the science conference statement: manifestations and management of chronic insomnia in adults June 13–15, 2005. Sleep 2005; 28(9): 1049–57

    Google Scholar 

  2. Winkelman J, Pies R. Current patterns and future directions in the treatment of insomnia. Ann Clin Psychiatry 2005; 17(1): 31–40

    Article  PubMed  Google Scholar 

  3. American Psychiatric Association. Sleep disorders: diagnostic and statistical manual of mental disorders, text revision. 4th ed. Washington, DC: American Psychiatric Association, 2000: 597–661

    Google Scholar 

  4. Lunesta® (eszopiclone) tablets 1 mg, 2 mg, 3 mg: US prescribing information. Marlborough (MA): Sepracor Inc, 2008 Feb

    Google Scholar 

  5. Blaschke G, Hempel G, Müller WE. Preparative and analytical separation of the zopiclone enantiomers and determination of their affinity to the benzodiazepine receptor binding site. Chirality 1993; 5(6): 419–21

    Article  PubMed  CAS  Google Scholar 

  6. Carlson JN, Haskew R, Wacker J, et al. Sedative and anxiolytic effects of zopiclone’s enantiomers and metabolite. Eur J Pharmacol 2001; 415(2–3): 181–9

    Article  PubMed  CAS  Google Scholar 

  7. GlaxoSmithKline. GlaxoSmithKline and Sepracor Inc. announce international alliance for commercialisation of Lunivia [media release]. 2007 Sep 11

  8. Karle J, Nielsen M. The mechanism of action and pharmacology of zopiclone. Rev Contemp Pharmacother 1998; 9(2): 77–87

    CAS  Google Scholar 

  9. Davies M, Newell JG, Derry JM, et al. Characterization of the interaction of zopiclone with gamma-aminobutyric acid type A receptors. Mol Pharmacol 2000; 58(4): 756–62

    PubMed  CAS  Google Scholar 

  10. Rosenberg R, Caron J, Roth T, et al. An assessment of the efficacy and safety of eszopiclone in the treatment of transient insomnia in healthy adults. Sleep Med 2005; 6(1): 15–22

    Article  PubMed  Google Scholar 

  11. Boyle J, Trick L, Johnsen S, et al. Next-day cognition, psychomotor function, and driving-related skills following nighttime administration of eszopiclone. Hum Psychopharmacol. Epub 2008 Mar 18

  12. Zammit GK, McNabb LJ, Caron J, et al. Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia. Curr Med Res Opin 2004; 20(12): 1979–91

    Article  PubMed  CAS  Google Scholar 

  13. Noble S, Langtry HD, Lamb HM. Zopiclone: an update of its pharmacology, clinical efficacy and tolerability in the treatment of insomnia. Drugs 1998; 55(2): 277–302

    Article  PubMed  CAS  Google Scholar 

  14. Maier G, Koch P, Caron J, et al. Dose proportionality and time to steady-state of eszopiclone in healthy adult volunteers following single and multiple dosing [abstract no. M1325]. AAPS Pharm Sci 2003; 5 (4)

  15. Anderson AJ, Maier G, Skolly SM. Pharmacokinetic interaction between eszopiclone and ketoconazole in healthy volunteers at steady state [abstract no. 137]. Pharmacotherapy 2005; 25(3): 474

    Google Scholar 

  16. Skolly SM, Niewoehner J, Maier G. Pharmacokinetic and pharmacodynamic interaction of eszopiclone and paroxetine in healthy subjects [abstract no. 12]. Pharmacotherapy 2004; 24(10): 1422

    Google Scholar 

  17. Maier G, Roach J, Rubens R. Evaluation of pharmacokinetic and pharmacodynamic interactions between eszopiclone and warfarin [abstract no. 125]. Sleep 2004; 27 Suppl.: 56

    Google Scholar 

  18. Caron J, Wessel T, Maier G. Evaluation of a pharmacokinetic interaction between eszopiclone and digoxin [abstract no. 124]. Sleep 2004; 27 Suppl.: 55–6

    Google Scholar 

  19. Leese P, Maier G, Vaickus L, et al. Esopiclone: pharmacokinetic and pharmacodynamic effects of a novel sedative hypnotic after daytime administration in healthy subjects [abstract no. 061.C]. Sleep 2002; 25 Suppl.: A45

    Google Scholar 

  20. Maier G, Hsu R, Broward M, et al. Evaluation of eszopiclone permeability using the Caco-2 in vitro model [abstract no. T2127]. AAPS Pharm Sci 2003; 5 (4)

  21. Gaillot J, Heusse D, Hougton GW, et al. Pharmacokinetics and metabolism of zopiclone. Pharmacology 1983; 27 Suppl. 2: 76–91

    Article  PubMed  CAS  Google Scholar 

  22. Gaillot J, Le Roux Y, Houghton GW, et al. Critical factors for pharmacokinetics of zopiclone in the elderly and in patients with liver and renal insufficiency. Sleep 1987; 10 Suppl. 1: 7–21

    PubMed  Google Scholar 

  23. Fernandez C, Alet P, Davrinche C, et al. Stereoselective distribution and stereoconversion of zopiclone enantiomers in plasma and brain tissues in rats. J Pharm Pharmacol 2002; 54(3): 335–40

    Article  PubMed  CAS  Google Scholar 

  24. Walsh JK, Krystal AD, Amato DA, et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep 2007 Aug 1; 30(8): 959–68

    PubMed  Google Scholar 

  25. Krystal AD, Walsh JK, Laska E, et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep 2003; 26(7): 793–9

    PubMed  Google Scholar 

  26. Scharf M, Erman M, Rosenberg R, et al. A 2-week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep 2005; 28(6): 720–7

    PubMed  Google Scholar 

  27. McCall WV, Erman M, Krystal AD, et al. A polysomnography study of eszopiclone in elderly patients with insomnia. Curr Med Res Opin 2006; 22(9): 1633–42

    Article  PubMed  CAS  Google Scholar 

  28. Fava M, McCall WV, Krystal A, et al. Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biol Psychiatry 2006; 59(11): 1052–60

    Article  PubMed  CAS  Google Scholar 

  29. Pollack M, Kinrys G, Krystal A, et al. Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Arch Gen Psychiatry 2008 May; 65(5): 551–62

    Article  PubMed  CAS  Google Scholar 

  30. Soares CN, Joffe H, Rubens R, et al. Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomized controlled trial. Obstet Gynecol 2006; 108(6): 1402–10

    Article  PubMed  CAS  Google Scholar 

  31. Rubens R, Wessel T, Caron J, et al. The effect of eszopiclone 3 mg compared with placebo in patients with rheumatoid arthritis and co-existing insomnia [abstract no. P02.014]. Neurology 2006; 66 (5 Suppl. 2): 78–79. Plus poster presented at the 58th Annual Meeting of the American Academy of Neurology; 2006 Apr 1–8; San Diego (CA)

    Google Scholar 

  32. Roth T, Walsh JK, Krystal A, et al. An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia. Sleep Med 2005; 6(6): 487–95

    Article  PubMed  Google Scholar 

  33. McCall V, Krystal A, Rubens R, et al. Two double-blind, placebo-controlled, 6-month trials of eszopiclone for insomnia: pooled analysis by race/ethnicity [abstract no. 0733]. Sleep 2006; 29 Suppl.: A249. Plus poster presented at the 20th Anniversary Meeting of the Associated Professional Sleep Societies, LLC; 2006 Jun 17–22; Salt Lake City (UT)

    Google Scholar 

  34. Krystal AD, Roach J. Efficacy of eszopiclone in the treatment of sleep-maintenance insomnia [abstract no. NR846 plus oral presentation]. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1–6; New York, 318

  35. Krystal A, Fava M, Rubens R, et al. Evaluation of eszopiclone discontinuation after cotherapy with fluoxetine for insomnia with coexisting depression. J Clin Sleep Med 2007; 3(1): 48–55

    PubMed  Google Scholar 

  36. Doghramji P, Winkelman J, Rubens R, et al. Evaluation of patient satisfaction: regimen of eszopiclone sleep satisfaction trial (RESST) [abstract no. 0737]. Sleep 2006; 29 Suppl.: A250. Plus poster presented at the 20th Anniversary Meeting of the Associated Professional Sleep Societies, LLC; 2006 Jun 17–22; Salt Lake City (UT)

    Google Scholar 

  37. Dundar Y, Boland A, Strobl J, et al. Newer hypnotic drugs for the short-term management of insomnia: a systematic review and economic evaluation. Health Technol Assess 2004; 8(24): i–x, 1–125

    Google Scholar 

  38. US FDA. FDA requests label change for all sleep disorder drug products [media release]. 2007 Mar 14

  39. Botteman MF, Ozminkowski RJ, Wang S, et al. Cost effectiveness of long-term treatment with eszopiclone for primary insomnia in adults: a decision analytical model [published erratum appears in CNS Drugs 2007; 21 (5): 405]. CNS Drugs 2007; 21(4): 319–34

    Article  PubMed  Google Scholar 

  40. Eisai Co. Ltd. Eisai enters into in-licensing agreement with Sepracor for eszopiclone insomnia treatment [media release]. 2007 Jul 27

  41. Infante M, Benca R. Treatment of insomnia. Prim Psychiatr 2005; 12(8): 47–56

    Google Scholar 

  42. Silber MH. Chronic insomnia. N Engl J Med 2005 Aug 25; 353(8): 803–10

    Article  PubMed  CAS  Google Scholar 

  43. Takeda Pharmaceuticals America Inc. Rozerem™ (ramelteon) tablets: US prescribing information [online]. Available from URL: http://www.rozerem.com [Accessed 2008 May 2]

  44. Sanofi-aventis US LLC. Ambien CR (zolpidem tartrate extended-release tablets): US prescribing information [online]. Available from URL: http://products.sanofi-aventis.us/ambien_cr/ambienCR.html [Accessed 2008 May 2]

  45. Sanofi-aventis US LLC. Ambien® (zolpidem tartrate) tablets for oral administration: US prescribing information [online]. Available from URL: http://www.sanofi-aventis.us [Accessed 2008 May 2]

  46. King Pharmaceuticals Inc. Sonata® (zaleplon) capsules: US prescribing information [online]. Available from URL: http://www.kingpharm.com [Accessed 2008 May 2]

  47. Questcor Pharmaceuticals Inc. Doral® (quazepam tablets, USP): US prescribing information [online]. Available from URL: http://www.doralforsleep.com/PDF/Doral_PI.pdf [Accessed 2008 May 2]

  48. Pfizer Inc. Halcion® triazolam tablets, USP: US prescribing information [online]. Available from URL: http://www.p-fizer.com [Accessed 2008 May 2]

  49. Mallinckrodt Inc. Restoril® (temazepam) capsules USP: US prescribing information [online]. Available from URL: http://www.restoril.com [Accessed 2008 May 2]

  50. ICN Pharmaceuticals Inc. Dalmane® (flurazepam hydrochloride) capsules for relief of insomnia: US prescribing information [online]. Available from URL: http://www.valeant.com [Accessed 2008 May 2]

  51. Watson Laboratories Inc. Estazolam tablet: US prescribing information [online]. Available from URL: http://www.watson.com/products [Accessed 2008 May 2]

  52. Dooley M, Plosker GL. Zaleplon: a review of its use in the treatment of insomnia. Drugs 2000; 60(2): 413–45

    Article  PubMed  CAS  Google Scholar 

  53. Swainston Harrison T, Keating GM. Zolpidem: a review of its use in the management of insomnia. CNS Drugs 2005; 19(1): 65–89

    Article  PubMed  Google Scholar 

  54. McCall WV, D’Agostino Jr R, Dunn A. A meta-analysis of sleep changes associated with placebo in hypnotic clinical trials. Sleep Med 2003; 4(1): 57–62

    Article  PubMed  Google Scholar 

  55. Morin CM. Measuring outcomes in randomized clinical trials of insomnia treatments. Sleep Med Rev 2003; 7(3): 263–79

    Article  PubMed  Google Scholar 

  56. McGechan A, Wellington K. Ramelteon. CNS Drugs 2005; 19(12): 1057–65

    Article  PubMed  CAS  Google Scholar 

  57. Dolder C, Nelson M, McKinsey J. Use of non-benzodiazepine hypnotics in the elderly: are all agents the same? CNS Drugs 2007; 21(5): 389–405

    Article  PubMed  CAS  Google Scholar 

  58. Barbone F, McMahon AD, Davey PG, et al. Association of road-traffic accidents with benzodiazepine use. Lancet 1998 Oct 24; 352(9137): 1331–6

    Article  PubMed  CAS  Google Scholar 

  59. Gustavsen I, Bramness JG, Skurtveit S, et al. Road traffic accident risk related to prescriptions of the hypnotics zopiclone, zolpidem, flunitrazepam and nitrazepam. Sleep Med. Epub 2008 Jan 26

  60. Terzano MG, Rossi M, Palomba V, et al. New drugs for insomnia: comparative tolerability of zopiclone, zolpidem and zaleplon. Drug Saf 2003; 26(4): 261–82

    Article  PubMed  CAS  Google Scholar 

  61. Jhaveri M, Seal B, Pollack M, et al. Will insomnia treatments produce overall cost savings to commercial managed-care plans? A predictive analysis in the United States. Curr Med Res Opin 2007; 23(6): 1431–43

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Paul L. McCormack.

Additional information

Various sections of the manuscript reviewed by: M. Bonnet, Veterans Affairs Medical Center, Dayton, Ohio, USA; C. Dolder, Wingate University School of Pharmacy, Wingate, North Carolina, USA; M.B. Scharf, Tri-State Sleep Disorders Center, Cincinnati, Ohio, USA; M.G. Terzano, Clinica Neurologica - Centro di Medicina del Sonno, Azienda Ospedaliera Universitaria di Parma, Parma, Italy; G.K. Zammit, Clinilabs, New York, New York, USA.

Data Selection

Sources: Medical literature published in any language since 1980 on ‘eszopiclone’, identified using MEDLINE and EMBASE, supplemented by AdisBase (a proprietary database of Wolters Kluwer Health | Adis). Additional references were identified from the reference lists of published articles. Bibliographical information, including contributory unpublished data, was also requested from the company developing the drug.

Search strategy: MEDLINE, EMBASE and AdisBase search terms were ‘eszopiclone’ and ‘insomnia’. Searches were last updated 21 May 2008.

Selection: Studies in patients with insomnia who received eszopiclone. Inclusion of studies was based mainly on the methods section of the trials. When available, large, well controlled trials with appropriate statistical methodology were preferred. Relevant pharmacodynamic and pharmacokinetic data are also included.

Index terms: Eszopiclone, insomnia, pharmacodynamics, pharmacokinetics, therapeutic use, pharmacoeconomics, tolerability.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hair, P.I., McCormack, P.L. & Curran, M.P. Eszopiclone. Drugs 68, 1415–1434 (2008). https://doi.org/10.2165/00003495-200868100-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200868100-00005

Keywords

Navigation